ire-1 rnase

D-F07 belongs to fluorescent dye-class tricyclic chromone compounds and is an IRE1 inhibitor (prodrug form containing an aldehyde-masked group) with cell permeability. This compound induces tumor cell apoptosis through inhibition of the IRE1/XBP1 pathway, exhibiting significant antitumor activity, and is suitable for related mechanism research and antitumor drug development.

B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells.

MKC8866 is a selective IRE1 RNase inhibitor (IC50: 0.29 μM in human vitro). MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibit prostate cancer (PCa) tumor growth.

4μ8C (IRE1 Inhibitor III) is a highly selective and potent inhibitor of IRE1α ribonuclease (RNase) activity (IC₅₀ ≈ 6–10 μM). By forming a covalent bond with the RNase active site of IRE1α, 4μ8C specifically inhibits its ribonuclease activity, thereby blocking the splicing of XBP1 mRNA. 4μ8C can be used in research on endoplasmic reticulum stress, the unfolded protein response, immune regulation, and tumor and metabolic diseases.